CRC (metastatic w/RASm; alone or combo w/pembrolizumab) | XPORT-CRC-041

This is a Phase 2 Open-Label Multicenter Study to Evaluate the Safety and Efficacy of Selinexor With or Without Pembrolizumab Versus Standard of Care in Previously Treated Metastatic Colorectal Cancer With RAS Mutations.

Please visit ClinicalTrials.gov for more information about this study.